text:
December 18, 2013 at 1:49PM This Chromium experiment takes the URL out of the address bar, because why not?
December 13, 2013 at 5:02AM Jolicloud 2 gets Feedly integration and a simpler interface for all your cloud services
December 4, 2013 at 11:25AM Google improves its Santa tracking with a Chromecast-ready Android app (video)
December 4, 2013 at 2:21AM Chrome OS scores a redesigned camera app that'll soon record video and upload to YouTube
November 11, 2013 at 3:22PM Google Chrome now lets you see which tab that unwanted music is coming from
November 7, 2013 at 3:56PM Chrome users on Windows will soon have to get extensions through Google's store
November 4, 2013 at 7:20PM Daily Roundup: Steam Controller hands-on, Lumia 929 leak, grim BlackBerry developments and more!
October 27, 2013 at 7:42PM Weekly Roundup: Surface 2 review, McLaren P1 'hypercar,' Google's Project Shield and more!
October 22, 2013 at 9:59PM Google to give parents more control with supervised user accounts in Chrome
October 17, 2013 at 6:26PM Google still makes lots of money, Motorola doesn't, and Larry Page wants to spend more on 'speculative' R&D
October 15, 2013 at 4:50AM Chrome OS 30 stable build adds select, drag-and-drop features for touchscreens
October 3, 2013 at 8:28PM Chrome 31 beta for Android brings home screen shortcuts, search-friendly tabs (updated)
October 1, 2013 at 2:47PM Chrome 30 hits the stable channel with new Android gestures and simpler search by image
September 19, 2013 at 4:42AM Apple now lets Windows users sync iCloud bookmarks with Chrome and Firefox
September 18, 2013 at 12:24AM Google's AdID, an anonymous identifier for advertising, could replace the aging cookie
September 12, 2013 at 12:00PM Evernote's Chrome Web Clipper adds new save options, sharing and Skitch features
September 11, 2013 at 6:37PM Google+ brings Snapseed-powered photo editing tools to desktop Chrome (video)
September 10, 2013 at 12:23AM Arcade Fire's 'Just a Reflektor' music video takes cues from your smartphone
September 5, 2013 at 12:43PM Chrome apps gain native powers and desktop launcher on Windows and Chrome OS, Mac, Linux versions to follow
September 5, 2013 at 11:21AM Chrome OS beta adds touchscreen support for selections, drag and drop (video)
August 26, 2013 at 7:47PM Google testing search-friendly tabs in stable versions of Chrome and Chrome OS
August 22, 2013 at 1:45PM Chrome 30 beta adds quicker access to search by image, improved gestures and much, much more
August 20, 2013 at 2:52PM Chrome 29 brings more intelligent omnibox suggestions, while Android users nab WebRTC support
August 12, 2013 at 5:45PM TweetDeck for web and Chrome gets New Tweet panel with image previews, as-you-type suggestions
August 9, 2013 at 4:19PM Google open sources two Web Lab experiments ahead of shutdown this Sunday (video)
August 7, 2013 at 9:38AM Finding passwords saved in Chrome is surprisingly easy, Google security lead sees no issue
July 28, 2013 at 11:50AM Chromecast bootloader exploit surfaces, opens up plenty of possibilities (video)
July 24, 2013 at 1:58PM Hands-on with Chromecast, Google's wireless HDMI streaming dongle (update: video)
July 24, 2013 at 10:00AM Google's 'breakfast with Sundar' is today at noon ET, get your liveblog here!
July 23, 2013 at 10:26PM Google lists Chromecast as a device in support docs, quickly removes it (updated)
July 20, 2013 at 2:46PM Chrome OS beta update brings 'immersive' mode, smarter app search and UI tweaks
July 17, 2013 at 2:59PM Chrome for iOS gets better integration with Google apps, fullscreen on iPad, access to full browser history
July 16, 2013 at 3:13PM Chrome beta brings improved suggestions to address bar, Android users get new WebRTC benefits
July 10, 2013 at 5:22PM Chrome for Android update adds fullscreen mode for tablets, Google Translate integration
July 9, 2013 at 5:28PM Outbound calls from desktop Gmail are back, with free calling to the US and Canada
July 9, 2013 at 6:21AM New Chrome developer tools bring Bluetooth, iTunes integration to packaged apps
June 19, 2013 at 4:06AM Evernote Web Clipper's new Gmail function saves copies of emails and attachments
June 12, 2013 at 11:06PM Google's latest Chrome Experiment lets you slam a cube at a friend's face (video)


text:
4th Day Echo
10 p.m., Friday February 22 | Cover.
Where: Knotty Pine
Phone: 513-741-3900
Address: 6947 Cheviot Road
Website: http://www.knottypinerocks.com/
The Reduced Shakespeare Company presents a comedy like no other, tracking and tying together the progression of the belly-aching form of art. Promising everything from "cavemen 'rock-rock' jo ...

subset: commoncrawl


text:
Eric is a full featured Python and Ruby editor and IDE, written in Python. It is based on the cross platform Qt GUI toolkit, integrating the highly flexible Scintilla editor control. It is designed to be usable as an everyday quick and dirty editor as well as being usable as a professional project management tool, integrating many advanced features that Python offers the professional coder. Eric includes a plug-in system, which allows easy extension of the IDE functionality with plug-ins downloadable from the net. Current stable versions are Eric4 based on Qt4 and Python 2 and Eric5 based on Python 3 and Qt4.
WebIssues is a multi-platform system for issue tracking and team collaboration. It can be used to store, share, and track issues with various attributes, description, comments, and file attachments. It is easy to install and use but has many capabilities and is highly customizable. Desktop and Web clients are provided.
QCAD is an application for computer aided drafting (CAD) in two dimensions (2D). With QCAD, you can create technical drawings such as plans for buildings, interiors, mechanical parts, or schematics and diagrams. QCAD can be easily extended through plugins and its very powerful and complete ECMAScript (JavaScript) interface.
Barcodes for Python is a library that can create EAN-13, Code-128A, Code128-B, Code128-C, and Gs1 barcodes. It also includes a CLI tool that can generate barcode image files and GTK+ and Qt GUI examples with printing support. The barcodes is produces have been verified using a cheap Deltaco (KB Wedge B519153) CCD handheld barcode scanner.


text:
GET ALL 3 OF OUR 2012 RELEASES FOR $52 Save $8.97 with the bundle of our three 2012 titles containing a total of 2 DVDs and 5 CDs: The Galactic Collective: Definitive Edition $24.99 The Galactic Collective: Live in Gettysburg $24.99 Lana Lane - El Dorado Hotel $10.99 The Galactic Collective: Definitive Edition contains a 2+ hour DVD of in-studio recordings with extensive interview and documentary footage + 2 audio CDs including the original Galactic Collective album plus a second audio CD, Echoes from the Collective. The Galactic Collective: Live in Gettysburg contains a 2 hour DVD of Erik's set at RoSFest 2011 along with an additional track recorded live in Cleveland. 2 audio CDs contain all the music from the DVD. El Dorado Hotel is Lana's 10th studio album and a spectacular symphonic production. |
ERIK NORLANDER - THE GALACTIC COLLECTIVE: DEFINITIVE EDITION 2012 USA DVD/2CD: $24.99 Now Shipping!!! The long-awaited DVD/2CD studio release from symphonic rock keyboard master, Erik Norlander, is now here. THE GALACTIC COLLECTIVE is the new take on the best of Erik's vast instrumental compositions written for Rocket Scientists, Lana Lane and his own solo albums over the years. Recorded on an amazing arsenal of classic analog synthesizers along with a top-notch band. THE GALACTIC COLLECTIVE is a must have for all fans of keyboard - oriented instrumental progressive rock. The DVD and 2CD set includes the complete album, ERIK NORLANDER - THE GALACTIC COLLECTIVE, both on CD and DVD with the complete in-studio video shot during the actual sessions (as seen on YouTube). The DVD includes extensive interview footage of Erik discussing each song, its conception and new interpretation for this project. A 2nd disc of well-crafted (not filler!) unreleased alternate versions and a new recording of Erik's classic arrangement of "Space: 1999" makes up the 2nd CD as Echoes from the Collective. Full color, detailed booklet with liner notes by Michelle Moog-Koussa. Also check out the live companion release, THE GALACTIC COLLECTIVE - LIVE IN GETTYSBURG. Released in partnership with Gonzo Multimedia, UK. Featuring Erik Norlander (keyboards), Freddy DeMarco (guitars), Mark Matthews (bass) and Nick LePar (drums) with special guests John Payne, Mitch Perry, Mark McCrite, Ron Redfield and Lana Lane. |
ERIK NORLANDER - THE GALACTIC COLLECTIVE: LIVE IN GETTYSBURG 2012 USA DVD/2CD: $24.99 Now Shipping!!! The DVD and 2CD set includes the complete album, ERIK NORLANDER - THE GALACTIC COLLECTIVE, performed LIVE at The Rites of Spring Festival 2011 along with the "Into the Sunset Suite" and the Norlander-penned Lana Lane songs, "Capture the Sun" and "Secrets of Astrology" creatively woven into medleys to complete the celestial sojourn with guest vocals by none other than Lana Lane herself! Erik's Modular Moog synthesizer, "The Wall of Doom," was used extensively at this concert, and band is introduced by Michelle Moog-Koussa. Full color, detailed booklet includes not only beautiful photos from the concert but also liner notes by Erik's synth tech, former Moog Music designer and ELP keyboard tech, August Worley, along with an additional article written by Erik himself especially for this release. LIVE IN GETTYSBURG is the inevitable companion to its partner release, THE GALACTIC COLLECTIVE - DEFINITIVE EDITION, that contains the complete studio recordings along with extensive video interviews. Released in partnership with Gonzo Multimedia, UK. Featuring Erik Norlander (keyboards), Freddy DeMarco (guitars), Mark Matthews (bass) and Nick LePar (drums) with special guest vocalists Lana Lane and Debrissa McKinney. |
LANA LANE - EL DORADO HOTEL 2012 USA CD: $10.99 Now Shipping!!! Download from iTunes and ReverbNation "El Dorado Hotel" hosts Lane's usual broad spectrum of musical styles and genres with a cohesiveness that fans of the artist will recognize instantly. The opener, "A Dream Full of Fire," is a new Lana Lane classic that blurs the line between prog metal and jazz stylings in a melange that only she can deliver. "Maybe We'll Meet Again" is a European-styled melodic AOR radio anthem blending classic rock with modern sensibilities. The song, "El Dorado," is a Lana Lane epic with a soaring chorus reminiscent of her classic, "Queen of Ocean." The robust "Darkness Falls" introduces an Irish folk style combined with a gothic metal element with its haunting choral vocals and arena-crafted chorus. Then "Hotels" is an acoustic track that evokes jazz standards like "Autumn Leaves." The tracks, "Believe," "Life of the Party," "Gone Are The Days" and "Moon God" add further threads to the "El Dorado Hotel" tapestry. The album closes with the 11-1/2 minute opus, "In Exile" that producer Erik Norlander describes as a "vintage progressive rock epic." Total Running Time - 62:31. Listen to the music. |
Last site update 13 December 2012
(c) 2012 Think Tank
Media Newsletter
index |


text:
Join Now
Join ePHOTOzine, the friendliest photography community.
Upload photos, chat with photographers, win prizes and much more for free!
A near full frame capture of a male Blackbird (Turdus merula) taken in the garden at the end of October against a background of reddening Autumn foliage.
Many thanks for your C&Cs on yesterdays upload. Always very much appreciated
Brand: | Canon |
Camera: | Canon EOS 5D MkIII |
Lens: | EF500mm f/4L IS USM +1.4x |
Recording media: | RAW (digital) |
Date Taken: | 28 Oct 2012 - 3:12 PM |
Focal Length: | 700mm 7.6m from subject, tripod |
Lens Max Aperture: | f/5.7 |
Aperture: | f/7.1 |
Shutter Speed: | 1/100sec |
Exposure Comp: | 0.0 |
Exposure Mode: | Aperture-priority AE |
Metering Mode: | Spot |
Flash: | Off, Did not fire |
White Balance: | Manual |
Title: | Male Blackbird (Turdus merula) |
Username: | teocali |
Uploaded: | 5 Jan 2013 - 11:19 AM |
Tags: | Bird, Blackbird, Foliage, Full frame, Garden, Male, Perching, Reddening, Turdus merula, Wild, Wildlife / nature |
VS Mode Rating |
102 (100% won) These stats show the percentage of wins and the rating score that your photo has achieved. You can go to the VS Mode by clicking on this icon. Signup to e2Signup to e2 to see which photo this has won or lost against in the vs mode |
Votes: | 66 |
Quote: Quality Sylvia
Subject and that awesome backdrop really make this
Post edit - Please accept my early UA - thought I would give it now, before owt else gets shortlisted and puts me in a quandry
THANK YOU so much for your UA, Adrian - really means a lot to me coming from a top class avian togger
A cracking shot of this handsome **** blackbird, the detail and clarity in the plumage is immaculate and you've captured him against yet another wonderful natural background
love it beautiful so clear like from me. christine
Love the detail in this blackbird Sylvia, still poorly here but have different anti b as of yesterday
Now that's just better than good Sylvia EC worthy and so it should be
Congratulations Sylvia, a very fine image and well deserved EC.
I am truly overwhelmed -thank you everybody for your C&Cs, with a special thank you to Pete for the EC and to Adrian(tomcat), David(Craggwildlife), Dean(WindowonWildlife), Richard(MossyOak) and Brian (bricurtis) for their User Awards. Really appreciated and treasured
Add a Comment
ePHOTOzine, the web's friendliest photography community.
Upload photos, chat with photographers, win prizes and much more.


text: Special ReportTuberculosis: New Faces of an Old Disease (page 2)March 23, 2009Continued from page 1. "The Perfect Storm": When TB drug-resistance and HIV/TB co-infection collide When drug-resistant TB emerges in vulnerable populations also infected with HIV the elements of a "perfect storm" are created. The results are catastrophic. The world woke up to this threat in 2006 after a hospital in KwaZulu-Natal in South Africa reported that 52 out of 53 patients co-infected with HIV and extensively drug-resistant strains of TB had died before their diagnosis could be confirmed and they could be put on treatment.21 MSF first encountered drug-resistant TB in eastern Europe and the former Soviet Union, where the problem of MDR-TB first emerged and the medical infrastructure was already in place for treating TB. However, with the spread of TB across increasing numbers of HIV positive populations in sub-Saharan Africa, the picture is now completely different. The medical infrastructures in these countries – already swamped by HIV, (for instance the estimated 5.5 million people living with HIV in South Africa)22, let alone other diseases – are ill-equipped to cope. Patient isolation – a counterproductive strategySome countries – such as South Africa – have adopted the policy of isolating DR-TB patients from the community as the national strategy. Diagnosed patients are admitted to regional, specialized treatment centers for at least six months, usually into congregate wards. The main argument is around the need to reduce community transmission by 'isolating' patients. However, there is little evidence that prolonged hospitalization improves adherence and prevents transmission, and there are even indications to the contrary. In addition, this policy raises difficult ethical questions. There are several reasons why isolation cannot continue to be the norm for all patients. Firstly, under-resourced and overburdened health services can't provide the required facilities, with the result that many patients are kept waiting without treatment. Secondly, there is now evidence that patients within the confines of such health facilities will actually pass on the disease to their fellow in-patients and health staff, even while they are receiving second-line therapy.23 But the overwhelming reason for not pursuing this blanket policy of hospitalization is that so many patients will simply not be able to tolerate the isolation in far-away specialized hospitals. They may lose their economic livelihoods and separation from their normal support networks makes treatment unbearable. This could result in many patients defaulting from such hospitals with dire consequences for themselves and with the risk of spreading infection back in the community. Furthermore, isolation could discourage people from being diagnosed and therefore drive the epidemic underground, leading to increased community transmission. 24 Out in the community: MSF pilots integrated care projectFor these reasons, in Khayelitsha, a township outside Cape Town in South Africa, MSF and local health authorities have been developing a community-based approach to treatment of patients infected with drug-resistant TB – most of whom are also infected with HIV. This model of care brings with it its own challenges including the need to train local health staff, give peer adherence support to patients, adapt patients' housing conditions to reduce transmission risks for family members, boost the rapid tracing of patients who default on treatment, and raise awareness more widely about the disease, how it can be treated and its spread limited. It is hoped that through this model of care more patients will be diagnosed and successfully treated if they are supported to follow treatment in their homes and communities. In addition, building treatment capacity at the primary care level will allow more patients to access care. Dr. Cheryl McDermid is the team leader for MSF's drug-resistant TB (DR-TB) pilot project in Khayelitsha, South Africa Once a patient is diagnosed with TB, we offer counseling so that the patient understands the disease. We educate patients about TB, make them aware that they can be cured, and explain how they can prevent transmitting the disease to others. An MSF counselor and a peer educator provide this support. Both are former DR-TB patients themselves, and are therefore able to counsel patients based on first-hand experience. A second counseling session ideally takes place at the patient's home with family members present. Again, we explain the disease, its transmission and treatment and how the risk of transmission at home can be reduced. Sometimes MSF assists the family by providing a separate sleeping space for the patient or installing a window. Ironically, many of the corrugated iron shacks in Khayelitsha provide adequate ventilation because of the gaps left in the buildings as a result of poor construction. All patients are invited to join a support group which meets weekly. These groups are excellent for encouraging patients just starting on treatment – they can meet people who have been on treatment for much longer, and learn how others cope with taking their TB drugs. An MSF counselor visits patients in hospital at least once every fortnight. These visits reduce feelings of abandonment and neglect and the counselor acts as a link between patients and families. Most patients with DR-TB do not need complex hospital care. To provide an alternative to sub-acute care, we are establishing a small inpatient facility with 12 beds. This will offer outpatient services but also allow us to treat inpatients for several weeks at a time in a healthcare environment that is closer to patient's family and friends. For patients whose treatment options have run out, the facility will give them the option to receive palliative care and spend the end of their lives close to loved ones. Our approach aims to allow patients to stay in or near their own homes and, to the greatest extent possible, to maintain a normal, autonomous life. Of the nearly 6,000 people diagnosed with TB in Khayelitsha in 2008, 196 have been diagnosed with DR-TB to date. 74 percent of patients with DR-TB were also infected with HIV. Conclusions and recommendations MSF calls for increased access to treatmentWe need a massive effort to ensure more patients have access to appropriate treatment. This means: Boosting access to better diagnostic methodsUntil a new easy-to-use and sensitive point-of-care diagnostic test for TB is developed, there is no alternative but to boost access to existing diagnostic tools. Additional TB culture facilities must be set up wherever possible. Significant international and national efforts to build the capacity of laboratory facilities will also be necessary if the WHO recommendation to screen patients at risk of DR-TB for drug resistance is to be implemented successfully. MDR-TB rates in many areas of the world are high enough to justify routine DST testing in all new TB patients. For people living with HIV, DST should be performed at the start of TB treatment, as far as possible, to avoid mortality due to unrecognized DR-TB. Rapid DST methods should be used whenever feasible for the initial screening of DR-TB. 25 Prioritizing TB and scaling-up drug-resistant TB treatment programsCurrent scale-up of TB treatment programs is far too slow to achieve the global target to treat 1.6 million MDR- and XDR-TB patients by 2015.26 What's more, this global target does not even include all new patients with MDR-TB: with more than one million people already with MDR-TB today and an additional 490,000 new cases emerging each year, many more will need treatment. The goal of treatment scale-up is unrealistic with the tools at our disposal today. Greater efforts are needed to accelerate scale up. Like tobacco control, MDR-TB requires an international response. An international agreement on TB with a specific focus on control and treatment of MDR-TB could strengthen the WHO's role towards countries that are not on track to control the MDR-TB epidemic. It would also draw the attention of policy makers to the MDR-TB problem. New treatment models, including patient follow up at community level, are needed in particular in high burden MDR-TB / HIV contexts. The current centralized, hospital-based model will not be replicable in many health systems. Removing the barriers preventing the supply of second-line drugsTo reduce drug costs and improve the supply of second-line drugs, it is necessary to identify more than one quality-assured producer for each of the drugs needed in a second-line regimen. A global scale-up of MDR-TB treatment should increase volumes sufficiently to attract further drug producers and to reduce the price thanks to economies of scale and competition. WHO leadership is needed to ensure that the drugs it recommends for second- and third-line treatment continue to be delivered to MDR-TB programs, even when no regulatory indication for TB treatment exists. Integrating TB and HIV careTB treatment is falling dramatically behind where it matters most: Africa. Routine HIV testing and care must be made available to TB patients and all HIV patients must be screened and have access to early diagnosis and treatment of TB. MSF calls for an end to the neglect of TB research and a new framework for innovation and accessMany of the formidable obstacles we face in treating and detecting TB today are due to the inadequacy of the tools at our disposal. Not enough is being done. Despite the presence of new actors and initiatives working in the field of TB diagnosis research, current research and development efforts are still woefully insufficient to deliver the diagnostic tests that answer the most urgent medical needs. We need tests that are more accurate than culture or microscopy, that give results fast and are simple enough to be used in remote settings. Although the situation has significantly improved in the last decade, the TB drug pipeline is also relatively weak. About 40 compounds are currently in the global TB drug pipeline.27 This might sound promising, but if we compare it to the 171 and 371 drugs currently in clinical development respectively for pain management28 and cardiovascular diseases29 and developed only by US pharmaceutical companies, the size of neglect for TB research and development becomes evident. Furthermore, 'attrition' rates mean that this is in fact falling far short of what is needed – on average only one compound out of 20 makes it through the development stages, while the other 19 are abandoned.30 TB vaccine research has made progress and today we have some candidate vaccines in the pipeline. However, they are all in the early stage of development and clinical testing will not be completed before the next seven to eight years. Moreover, after the vaccines are tested singularly, further clinical research will need to be conducted to identify the most effective combination of priming and boosting vaccines. Therefore, an effective vaccine for TB is still years away and sustained funding will be necessary to reach this goal. We need a massive push to get new tools for TB. This means: New tools that respond to needsCurrently many different research agendas co-exist, and the most urgent needs don't necessarily attract the most investment. For diagnostics, for example, the needs of patients that are falling through the net must be prioritized. We need tools that work for children, for HIV positive patients, for all forms of active TB, and that can determine drug resistance. This may mean using samples other than sputum, which is so problematic for many patients. Looking at the peripheral levelDiagnostic developers need to focus on the peripheral level. They must concentrate on developing tools that can be used as close as possible to a patient's bedside. This would allow diagnosis to be carried out at the places where the majority of patients are seen and ensure that patients are immediately enrolled into appropriate treatment, avoiding the spread of disease. Boosting clinical trial capacityMore clinical trials are needed for the validation of tests and new drugs. Yet only US$20 million is spent annually worldwide for clinical trials for TB drugs compared to around US$300 million for HIV drugs in the US alone.31 In order to get more clinical trials done, funding needs to be fast tracked, and building of clinical trial capacity in endemic countries must become a priority. This requires a concerted effort of its own. Boosting clinical trials for MDR-TB drugsImprovements in MDR-TB treatment are critically urgent not only because of the current desperate situation in MDR-TB treatment but also because an entirely new first-line regimen for TB that would also address the problem of drug-resistant TB is many years away. . New drugs that are developed for TB should undergo trials in MDR-TB patients. A series of trials will be necessary to identify the best regimens and to integrate any new compound in the MDR-TB treatment regimen. A new initiative, Research Excellence to Stop TB Resistance (RESIST-TB) has been created to address this gap, but lacks crucial funding. This must change. Ensuring access to knowledgeCooperation among different research projects must be encouraged, and access to knowledge and others' research facilitated, for example through promising open source initiatives. Spending more money nowTB predominantly affects developing countries. As a result, TB research has been neglected through a lack of market incentives for pharmaceutical companies to invest in this area. The shortfall is colossal. Funding needs are estimated at around US$2 billion,32 yet barely US$400 million is spent today. European countries' contributions are particularly weak.33 Supporting alternative mechanisms to finance research and development and support accessThe current system for stimulating and rewarding research into and development of medicines, diagnostics and vaccines relies predominantly on the high prices that can be secured for health products developed, notably through granting monopoly and other intellectual property rights. It is no secret that the system is broken. Alternative mechanisms that stimulate research and development into neglected diseases, but also ensure that any products developed remain affordable and accessible to those in need, must be explored. We need a combination of larger and more sustainable 'push' funding through grants to researchers and academics, and 'pull' funding, through mechanisms such as a prize fund. Backing a TB diagnostic test prize fundPrize funds that separate the cost of research from the price of the finished product mean that any developed drug or diagnostic test can be priced more affordably for developing countries. They also allow donors to steer research towards areas of priority needs by determining in advance what medical innovation deserves to be rewarded. In April 2008, at an expert roundtable discussion convened by MSF, TB researchers, economists and campaigners showed considerable interest in a proposal for a prize fund that would encourage the development of an easy-to-use, point-of-care TB diagnostic test. The governments of Barbados and Bolivia subsequently made such a proposal to the WHO. They suggested exploring multiple prizes: for the development of a low-cost rapid diagnostic test for TB; for new treatments for Chagas disease; for a priority medicines and vaccines prize fund to reward mechanisms for new cancer treatments in developing countries; and for a licensed products prize fund for donors. Putting patents into a patent poolThe idea behind a patent pool is that different patent-holders, such as companies, universities and research institutes, make their patents and other relevant intellectual property available to others on a voluntary basis through the pool. The pool then acts like a one-stop patent shop and allows other companies and researchers to access those patents in exchange for a fair royalty payment to the patent-holders. UNITAID is currently setting up a medicines patent pool. The pool will initially focus on HIV and seek to boost access to new antiretroviral drugs in developing countries and to stimulate follow-on innovation such as the development of fixed-dose combinations or pediatric formulations. Once established, the patent pool could be extended to TB. Companies should collaborate with UNITAID with a view to voluntarily contribute their patents. Glossary of termsActive tuberculosis. A form of TB characterised by active growth and multiplication of bacteria in the infected part(s) of the body, leading to the destruction of infected tissues and organs. As opposed to latent TB it needs immediate treatment. Adherence. A patient is fully adherent to a treatment if the drugs are taken at the right dose, at the right time for the whole duration of the treatment course; if no doses are missed; if no appointments for follow up are missed; and if the patient feels co-responsible for his or her treatment. For TB, one patient out of two will have difficulties in following the treatment course. Poor adherence may lead to treatment failure, the development of drug resistance, and increases the threat of transmitting the disease to others. Ambulatory treatment. Also called outpatient treatment, ambulatory treatment for TB is delivered and directly observed by a caretaker (see DOT), but without keeping the patient hospitalised. Patients living near a health centre will go to the centre on a daily basis to collect their treatment. Patients living further away will be visited by a community health worker who will deliver treatment to the patients' home. Combination therapy. Therapy characterised by the simultaneous administration of two or more drugs. Completion. A type of treatment outcome used to determine the success (or lack of success) of treatment for individual patients. Treatment completion applies to patients who have undergone a whole treatment course but for whom there is no confirmation of cure. This can either be because the absence of M. tuberculosis from the patient's sputum was not correctly verified or because the patient was not able to produce sputum. This definition will also be used for patients who initially enrolled as smear negative, as in their case a negative sputum sample is not a confirmation of a specific response to treatment. Culture. Bacterial culture is a laboratory method to multiply bacteria in order to assess their presence or not in a patient's sample. This is done by letting the bacteria grow in predetermined culture media under controlled laboratory conditions, outside the natural environment where they usually grow (e.g. for TB, the human body). Culture medium. A liquid or solid substance with a composition that supports the growth of micro-organisms or cells outside the natural environment where they usually grow. Default. A patient who defaults has interrupted treatment for over two months. Defaulters who eventually return to access healthcare will usually be re-started on treatment, but the treatment regimen used will be stronger, with initially five (instead of four) drugs, as the patient might have developed resistance by virtue of defaulting. DNA. Deoxyribonucleic acid. This is the molecule that encodes the genetic information that determines the development and functioning of living organisms and some viruses. DOT. Directly-Observed Treatment. As opposed to self-administered treatment (SAT), DOT involves a patient taking medication in front of a healthcare or community worker, in order to ensure that the lengthy regimen is taken in full by the patient. DOTS. Directly-Observed Treatment, Short-course is WHO's recommended strategy for detection and cure of TB. DOTS combines five elements: political commitment, access to microscopy services for diagnosis of TB, reliable drug supplies, surveillance and monitoring systems and use of highly efficacious regimes with direct observation of treatment. Drug resistance. When a drug used to treat tuberculosis is in fact ineffective against a strain of M. tuberculosis, the bacteria is said to be resistant to the drug (as opposed to drug-susceptible or drug-sensitive). Drug sensitivity testing. Sometimes also called antibiogram, Drug Sensitivy Testing, or DST, is a technique to determine which drugs work and which don't. It is done by exposing the TB bacilli to a culture-medium enriched by the antibiotic: if the bacteria are able to grow, the antibiotic is ineffective and the bacteria are resistant to the drug. If there is no growth, the antibiotic is proven to be effective, and the bacteria are sensitive or susceptible to the drug. Drug-susceptible TB. Bacteria are said to be sensitive to a drug when the drugs are effective in killing or stopping the multiplication of bacteria in the body and can therefore clear the infection. The strains of TB which are sensitive to all first-line drugs are called drug-susceptible. Extra-pulmonary TB. Form of TB where M. tuberculosis infect parts of the body other than the lungs. This is most commonly the lymph nodes, bones, central nervous system, cardiovascular and gastrointestinal systems. First-line drugs. The drugs used as the first resort to treat a disease. In the case of TB, the following five drugs are usually chosen: isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z) and streptomycin (S). These drugs are highly effective in drug-susceptible TB and patients usually tolerate them well. Latent TB. A form of TB characterised by the presence in the body of M. tuberculosis in a "dormant" state. In other words, they are not actively growing or multiplying. This form of the disease is not contagious. As opposed to active TB, most of the time, no treatment is needed. MGIT. MGIT stands for Mycobacterium Growth Indicator Tube. A diagnostic technique that contains a liquid medium releasing fluorescence when Mycobacteria are growing. The fluorescence is detected by a machine. The huge benefit of MGIT is the shorter time lag until a positive result can be obtained (8-10 days compared with 4-6 weeks for conventional culture media). But MGIT requires a well equipped laboratory, constant power supply and well trained staff. Microscopy. Microscopy is currently the most commonly used technique to diagnose TB. Two to three sputum samples are taken from the patient and the sample will be stained and later read under the microscope. If TB bacilli are present, they occur in the form of small red rods, while the rest of the sample is blue. Mycobacteria. Types of bacteria, of the genus Mycobacterium, that cause diseases such as TB and leprosy. Mycobacterium tuberculosis or M. tuberculosis. A pathogenic bacterial species of the genus Mycobacterium and the causative agent of most cases of TB. First discovered in 1882 by Robert Koch. Outpatient treatment. See ambulatory treatment. Pathogen. Any disease-producing agent (e.g. virus, bacteria, fungi). Peripheral level. In the organisation of health systems, the peripheral level represents the first point of contact of a person who is unwell with the health services. In low- and middle-income countries, peripheral health facilities are often located in rural and remote areas. Point-of-care testing. Testing at the point-of-care means that diagnosis is carried out as close as possible to the site of patient care. The driving notion behind point-of-care testing is having a test as convenient to the patient as possible and giving immediate results that can lead to prompt initiation of treatment. Pulmonary TB. Form of TB where M. tuberculosis bacteria are infecting the lungs. Push and pull mechanisms. 'Push' financing mechanisms are those that invest upfront in research to stimulate the development of new products. 'Push' programmes provide direct funding through, for example, grants to universities or government laboratories. In contrast, 'pull' mechanisms are economic devices designed to create or secure a market, thereby improving the likelihood of a return on financial investments and thus making such investment more attractive. Reagent. A chemical agent used for chemical reactions. Reagents are used in medical laboratories to facilitate reactions which than can confirm or reject a diagnosis. Second-line drugs. Second-line drugs are used when the first-line drugs are no longer effective to cure a patient. They are less effective against M. tuberculosis and have many more side-effects than first-line drugs. Sputum smear-positive or smear-negative TB. We speak about sputum smear-positive TB when M. tuberculosis bacteria can be identified in the sputum of patients through examination with a microscope. Sputum smear-negative TB, on the contrary, is when bacteria can not be identified in the sputum of patients. TLA. Thin layer agar. A solid culture medium used to facilitate the rapid culturing of M. tuberculosis. The TLA method is cheaper and easier to handle than MGIT and therefore a promising technique for more remote settings.


text:
All the latest info about marketing and promoting yourself on the web.
Natural health, body and mind in balance.
Los Angeles Car Accident Lawyer Vibhu Talwar has been representing clients in Southern California. Our car accident attorneys are here to help you.
Fat Lester's blog for the discussion of topics relating to health, medicine, nutrition and various random topics.
Learn more about Nassimi Development's San Diego SEO Services. Get your site to the top of Google with us.


text:
Author Guidelines
All entries should focus on providing a clear and accessible description of the subject. Authors should feel free to sequence the presentation of facts and descriptions to engage readers, while taking care to avoid overly involved or esoteric explanations. The goal is to inform readers by providing basic information and explaining significance.
Entries must be submitted electronically through the workshop on the Oregon Encyclopedia web site. Questions about that process can be directed to the editorial office (firstname.lastname@example.com).
All entries are subject to external review, fact-checking, and copy editing. Authors have the opportunity to respond to reviewers' suggestions and to revise their entries. The editors reserve the right to revise the accepted manuscript for clarity, consistency, style, syntax, and punctuation.
There are five categories of entries: biography, events, place, institutions and groups, and biota. As much as possible, entries should include the following:
Biography: Begin with what field of endeavor, talent, or skill makes the person important to Oregon. Provide a brief outline of the person's life, with specific reference to significant relationships to Oregon's history and culture. What are the person's principal accomplishments? What are the person's significant relationships to events, places, institutions, and organizations in Oregon? What is the person's legacy? What difference has the person made to Oregon?
Model Biographies: "George Aguilar, Sr.," by Jarold Ramsey and "H.L. Davis," by Glen A. Love.
Events: Describe the event and its time, location, and origin. What part in Oregon history did the event play? What led up to it? What organization(s) and individual(s) are associated with the event? Describe the aftermath of the event and its social, cultural, or political consequences. What is the event's legacy?
Model Events: "Hood to Coast Relay," by Joy Margheim and "Vortex I," by William G. Robbins.
Places: Describe the location of the place and its significance to Oregon over time. To what and to whom is it related? What economic, social, political, and spiritual importance does the place have for Oregon?
Model Places: "Mt. Hood Freeway," by Val Ballestrem and "Silicon Forest," by Craig Wollner.
Institutions & Groups: Describe the background and development of the institution or group. What is the significance to Oregon history and culture, including economic, social, political, spiritual, or aesthetic connections? What significant individuals, events, and places are related to the institution or group? What is the relationship to other institutions, agencies, places, and communities?
Model Institutions and Groups: "Ku Klux Klan," by Eckard Toy and "Oshu Nippo," by George Katagiri.
Biota: Describe the flora/fauna and its relation to Oregon. Describe its significance to the natural landscape, including references to agriculture, geography/geology, economics, weather, and aesthetics. What social impact does it have? How does it affect Oregon's food or fiber industries?
Model Biota: "Sugar Pine," by Frank A. Lang and "Port Orford Cedar," by Frank A. Lang.
Documentation: All entries must rely on existing scholarship, and authors must include documentation for quotes and specific information. Include documentation as parenthetical notes (author, date, page number) and provide the full citation to this documentation using the add source button. The references will be used in the review process to assess entries and essays. Notes will be removed in published entries, with sources appearing at the end of each entry. The Workshop system strips entry text of most formatting, including superscript citations, so we recommend authors use parenthetical citations.
Suggested Readings: Authors of entries up to 1000 words should submit as many as three suggested readings. Authors of essays 1000 words or more should submit up to five suggested readings. Authors can include these sources using the add source button, or they can enter these as a "Note to Editor." Authors can also list these at the bottom of the entry text, but we do not recommend this as the Workshop system will include this text as part of the overall word count.
Audience: The Oregon Encyclopedia will be a reference for general readers, teachers, and students. Authors should write for readers who have a range of ages and experience.
Originality: All essays and entries must be original and should not have been previously published, either in print or on the World Wide Web.
Style: Authors are encouraged to write in their own individual styles. They should write clearly and concisely and make sure that entries are focused and lacking in ambiguity. Although entries should reflect the authors' scholarly interpretations and professional judgment, they must be free of bias or personal opinion.
Controversial Topics: Where there is the potential for a topic to be controversial and there is not a significant corpus of scholarly work available, authors should handle the topic with fairness and respect.
Jargon: Authors should avoid using jargon and explain any local or specialized terminology.
Quoted Materials: Entries can include quotes from the work of scholars and other experts (with a reference to a source). Long quotations should be avoided, along with quotations from materials that require permission to reprint, such as poetry and lyrics.
Images: Authors are encouraged to submit suggestions for appropriate images (e.g., maps, photographs, artworks), film clips, and audio and video clips that could accompany their entries. Authors should submit captions and credits for all supplementary materials.
Keywords and Cross References: Authors are encouraged to identify keywords and cross references in their entries.
Style Guide: Chicago Manual of Style, 15th edition
Suggested Writing Guides: Elements of Style, by William Strunk and E.B. White, and The Columbia Guide to Online Style, by Janice Walker and Todd Taylor.


text:
My Chemical Romance, Neon Trees and The Architects at Terminal 5, 4.22.11
I must write about the line, as it was the most epic clusterfuck I have ever been party to. Because the sidewalk on the side of the street where the venue is is closed for repairs, they lined us up on the other side of the road. In this shady part of town, there's merely a long tunnel and then the West Side Highway. There were probably five hundred people in line by five (doors were at 7) and at least a thousand by the time doors opened. To try to keep the line from stretching too far down the access road to the highway, security asked us to bunch up and fill the sidewalk. So people started running. In the successive three "bunches", all sense of who had arrived then was lost. I just hope the poor kids who stayed overnight got up front.
The Architects: They begin with a long Spanish overture, like we're about to see a play about Zorro instead of straight classic punk. Choosing this band and Neon Trees is a good way to show the evolution of MCR, but I worry that this opener is lulling the hardcore old Jersey punk fans into a false sense of security. The lead Architect rocks harder than I've ever seen anyone rock a baby blue guitar.
They ask if we want to dance, then proceed to play a track so rockabilly that I half expect it to be a Brian Setzer cover. Their set spans the gap between The Misfits and Gaslight Anthem, with some songs that are almost country and some that are definite punk. But they're fron Kansas City. And they're wildly charming. CDs will be purchased.
Neon Trees: The people behind us are loudly making fun of lead singer Tyler's antics, his deep back bends and his high kicks. It's like they don't know that Gerard Way is on next. Tyler's mom is here and he makes all wave at her. She knows all the words and has Kate Gosselin's haircut and I love her.
I really think Elaine is the best female drummer rock has seen since… well, since forever. They make the kinda weird decision to end with "Farther Down", a track that's not on their brilliant full-length Habits and is kind of a slow-jam. Still, I was impressed. And I danced, which is the important thing.
My Chemical Romance: Frank Iero is aging backwards. He's wearing a pullover and a collared shirt and he looks about 15. He looks like the well-meaning neighborhood kid that Mrs.Way pays $20 an hour to watch her kids while she goes to the grocery store. Then again, instead of his "trust me" in the middle of "I'm Not Okay," he spits at the mic.
There is a spotlight pointed at Ray Toro's groin. We are calling this the Katie Spot.
I will say that this band seems as loving of their fans as they've ever been. Gerard takes the time to thank the new fans, the old fans, and the fanclub.
Touring keyboard star James Dewees gets his keyboard solo as always, but it's shorter. Gerard takes this opportunity to lie down.
I've said before that new album standout "Planetary (Go!)" is obviously a lost Fischerspooner track, but it doesn't occur to me until right now that "Destroya" is clearly a late-90s Nine Inch Nails b-side.
The sharp turn this band has taken is most clearly seen when they play their very first single, "Vampires Will Never Hurt You." It's a thrasher, chaotic and not bound to the conventions of popular music. I'm not entirely sure there are verses. It's almost the same four bars over and over, the sort of thing that is the bread and butter of scuzzy punk bands, but so divorced from the precise bombast of new-era MCR that this is essentially a cover. And not a cover that the band seems particularly jazzed to play.
Even though the line was bullshit and the floor was a mess (the most active pit I've seen in quite some time; I can't believe no one was injured), the band brought the energy. Plus, they brought openers who actually warmed the crowd up, getting us progressively more amped until the headliner started. It reminded me what the point of openers is: to stretch before your marathon. And shit, at the end of a My Chem show, it feels a little like you've run a marathon. But at least they ran it with you.


text:
You're watching...
Jenna Lee goes aboard 'America's tall ship'
Tour of U.S. Coast Guard Cutter Eagle
May 25, 2012
Capt. Eric Jones
You're watching...
Tour of U.S. Coast Guard Cutter Eagle
May 25, 2012
Capt. Eric Jones
Also in this playlist...
Auto-advance: ON
Auto-advanceThis transcript is automatically generated
Memorial Day weekend -- upon -- and fleet week is in full swing right here in the Big Apple.
I celebrating the achievements of our brave men and women in uniform and I had the privilege privilege that the deep privilege recently at taking a climb.
-- the US Coast Guard cutter eagle.
The eagle is called America's tall ship.
For a reason take a look.
Captain -- this is one -- the oldest.
-- in the -- for the Coast Guard -- 76ers.
And what does this should be round -- -- her primary mission is to -- coastguard academy cadet.
Us and Coast Guard officer candidates basically cranking them with the -- teaching -- teamwork leadership.
And all the various scales navigation firefighting.
Routine of the day I have seen so that they can -- -- Coast Guard -- -- obviously -- issue like this going to battle.
-- -- I get good.
She was actually built as a training ship -- by Germany.
The opening month civil courts she was a war reparations in the United States afterwards and.
They no longer efficient they're going to battle absorb it we often think that because -- -- think and act and the video that you might see and people being rescued at sea.
I'm the people that do that rescuing active members of the Coast Guard I have some of the -- on this and.
Absolutely when you meet an officer on the Coast Guard usually.
In charge of a ship for us.
Sector and one of your major ports they more than likely -- trained on board eagle.
Because it takes so many people to handle eagles' 23 sales.
It naturally lends itself to teamwork coordination and communication and -- how many people would be -- -- -- it -- -- time.
I normally sale during the summer anywhere between 205 and 230.
How how challenging is that -- in person out.
Yes absolutely -- -- the -- is a community in its own right hand so you have to deal you get to see each other at your best in -- worse and you get to see the ocean.
At her best and worst that's what I think -- -- the scariest part of me standing up here during a storm.
Would be really nerve -- have you been -- some really bad storms and some that scenes we certainly absolutely.
Two years ago we -- the back side of hurricane Alex we had a wonderful.
Ride it was rough but it was -- -- ship was traveling fourteen knots for two days straight.
And we tore across the Gulf of Mexico and.
Again there were perhaps a few that -- seasick and there are moments -- everyone was uncomfortable but everyone's got crazy stories to tell about it.
What do you think Americans just know about me.
Those currently do well we're we're proud to be part of the three sisters -- services -- -- the Marine Corps and Coast Guard.
And we've been around serving together.
Since the war of 1812 when it was the revenue marine the Marines and the US navy.
As matter of fact this weekend fleet week New York is.
Part of our commemoration of the bicentennial of the war of eighteen to.
What does it mean memorial stadium.
Gosh I mean for me.
When I get stopped on the street and someone says thank you for your service all I can says I'm honored to be able to -- For me I always think back to my father who served in Vietnam and obviously.
All those who served in world war two and the hardships they faced and really.
For Memorial Day I really think they're the ones that to honor the most certainly.
Those men and women right now.
Better over in the Middle East and another conflict areas in the world they're the ones that.
We should always -- thinking of first and foremost and with the hope that that young men and women that are training on eagle here.
I don't want -- -- -- Standing -- for that service.
Well said captain Jones and thank you captain Jones and his entire crew for letting us.
Take -- time there we appreciate it we'll be right back.
Filter by section